GSK Settles BOOSTRIX Marketing Lawsuit Amid Ongoing Scrutiny of Pharmaceutical Advertising Practices

GSK Settles Class Action Over BOOSTRIX Marketing Practices

GSK Plc has recently reached a settlement in a class action lawsuit that revolves around allegations concerning the misleading advertising of its pertussis vaccine, BOOSTRIX. The lawsuit, spearheaded by Lori DeCostanzo, scrutinized an advertising campaign titled "Big Bad Cough" that ran from May 20, 2016, to May 20, 2020, and claimed that BOOSTRIX protects against the transmission of whooping cough. The settlement will provide financial compensation to individuals who received the BOOSTRIX vaccine in New York during this specific timeframe, especially those who were vaccinated for the benefit of others.

Under the terms of the settlement, those eligible can claim $50 upon proving their vaccination or $10 if they cannot provide documentation. It's noteworthy that claimants must file by June 8, 2026, to qualify for compensation, which can be processed either online or through request forms. GSK continues to assert that it has done no wrong in this matter, but the settlement aims to address concerns raised about the activities related to BOOSTRIX advertising and ultimately offers monetary relief to affected individuals. Additionally, individuals who choose not to submit a claim will be bound by the settlement terms and relinquish their right to pursue separate legal action against GSK.

Alternatively, claimants have the option to secure their right to litigate by excluding themselves from the settlement by May 11, 2026. This could attract a number of individuals who wish to challenge the allegations through court proceedings. Furthermore, there is an upcoming fairness hearing scheduled for July 2, 2026, for those who may wish to voice any objections regarding the settlement terms. This development highlights the increasing scrutiny pharmaceutical companies face regarding their marketing practices, especially as the industry grapples with maintaining ethical guidelines while promoting healthcare solutions.

In a separate but related development, the U.S. Food and Drug Administration (FDA) has approved the expanded use of Wellcovorin (leucovorin calcium) tablets, significantly enhancing its application in treating patients undergoing chemotherapy. Previously utilized primarily for colorectal cancer, this wider approval signals a significant shift that could benefit a broader patient population. The decision reflects the FDA’s commitment to high-quality treatment options and the ongoing need for innovative therapies in the pharmaceutical sector.

Overall, while GSK navigates legal challenges around its marketing practices, advancements like the expanded use of Wellcovorin serve as a reminder of the industry's potential to improve patient outcomes and deliver life-saving medications.